SH PHARMA Subsidiary Shandong Xinyi Gains Approval as Marketing Authorization Holder for Trazodone Hydrochloride Tablets

Stock News05-28

SH PHARMA (601607.SH) announced that its subsidiary, Shandong Xinyi Pharmaceutical Co., Ltd., recently received a "Drug Supplement Application Approval Notice" (Notice No.: 2026B02904) from the National Medical Products Administration. The notice approves the transfer of the marketing authorization for Trazodone Hydrochloride Tablets to Shandong Xinyi Pharmaceutical Co., Ltd.

Trazodone Hydrochloride Tablets, a product originally approved for marketing in China in 2025 by Hebei Longhai Pharmaceutical Co., Ltd., are indicated for the treatment of depression and are effective for patients with or without accompanying anxiety. In May 2026, Shandong Xinyi submitted a registration application to the NMPA for the change in marketing authorization holder for this drug, which has now been approved.

As of the announcement date, the company has invested approximately RMB 5.2 million in this product.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1124808838?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-28 15:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124808838","market":"sh","top_or_hot":-1,"title":"SH PHARMA Subsidiary Shandong Xinyi Gains Approval as Marketing Authorization Holder for Trazodone Hydrochloride Tablets","media":"Stock News","content":"<p>SH PHARMA (601607.SH) announced that its subsidiary, Shandong Xinyi Pharmaceutical Co., Ltd., recently received a \"Drug Supplement Application Approval Notice\" (Notice No.: 2026B02904) from the National Medical Products Administration. The notice approves the transfer of the marketing authorization for Trazodone Hydrochloride Tablets to Shandong Xinyi Pharmaceutical Co., Ltd.</p>\n<p>Trazodone Hydrochloride Tablets, a product originally approved for marketing in China in 2025 by Hebei Longhai Pharmaceutical Co., Ltd., are indicated for the treatment of depression and are effective for patients with or without accompanying anxiety. In May 2026, Shandong Xinyi submitted a registration application to the NMPA for the change in marketing authorization holder for this drug, which has now been approved.</p>\n<p>As of the announcement date, the company has invested approximately RMB 5.2 million in this product.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SH PHARMA Subsidiary Shandong Xinyi Gains Approval as Marketing Authorization Holder for Trazodone Hydrochloride Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSH PHARMA Subsidiary Shandong Xinyi Gains Approval as Marketing Authorization Holder for Trazodone Hydrochloride Tablets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-28 15:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SH PHARMA (601607.SH) announced that its subsidiary, Shandong Xinyi Pharmaceutical Co., Ltd., recently received a \"Drug Supplement Application Approval Notice\" (Notice No.: 2026B02904) from the National Medical Products Administration. The notice approves the transfer of the marketing authorization for Trazodone Hydrochloride Tablets to Shandong Xinyi Pharmaceutical Co., Ltd.</p>\n<p>Trazodone Hydrochloride Tablets, a product originally approved for marketing in China in 2025 by Hebei Longhai Pharmaceutical Co., Ltd., are indicated for the treatment of depression and are effective for patients with or without accompanying anxiety. In May 2026, Shandong Xinyi submitted a registration application to the NMPA for the change in marketing authorization holder for this drug, which has now been approved.</p>\n<p>As of the announcement date, the company has invested approximately RMB 5.2 million in this product.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0184","symbol_name":"上海国资改革","start_time":0,"source_url":"","article_id":"1124808838","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124808838","pubTimestamp":1779954463,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SH PHARMA (601607.SH) announced that its subsidiary, Shandong Xinyi Pharmaceutical Co., Ltd., recently received a \"Drug Supplement Application Approval Notice\" (Notice No.: 2026B02904) from the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601607":"上海医药","BK0184":"上海国资改革","02607":"上海医药","BK0028":"国家队","BK0097":"医药电商","BK0099":"上海本地重组","BK0020":"浦东新区","BK0183":"MSCI概念","BK0209":"零售","BK1197":"保健护理产品经销商","BK0188":"融资融券","IPOS":"Renaissance International IPO ETF","BK0012":"证金概念","BK0196":"行业龙头","BK0175":"白马股","BK0187":"一线龙头"},"translate_title":"上海医药子公司山东信谊获得盐酸曲唑酮片上市许可持有人批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":1,"IPOS":1,"02607":1},"content_text":"SH PHARMA (601607.SH) announced that its subsidiary, Shandong Xinyi Pharmaceutical Co., Ltd., recently received a \"Drug Supplement Application Approval Notice\" (Notice No.: 2026B02904) from the National Medical Products Administration. The notice approves the transfer of the marketing authorization for Trazodone Hydrochloride Tablets to Shandong Xinyi Pharmaceutical Co., Ltd.\nTrazodone Hydrochloride Tablets, a product originally approved for marketing in China in 2025 by Hebei Longhai Pharmaceutical Co., Ltd., are indicated for the treatment of depression and are effective for patients with or without accompanying anxiety. In May 2026, Shandong Xinyi submitted a registration application to the NMPA for the change in marketing authorization holder for this drug, which has now been approved.\nAs of the announcement date, the company has invested approximately RMB 5.2 million in this product.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1124808838","isCrawlerRequest":true}